{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T06:09:51Z","timestamp":1761718191172,"version":"3.38.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1097\/maj.0b013e3182113658","type":"journal-article","created":{"date-parts":[[2011,10,8]],"date-time":"2011-10-08T07:27:22Z","timestamp":1318058842000},"page":"356-364","source":"Crossref","is-referenced-by-count":11,"title":["Rofecoxib and Clinically Significant Upper and Lower Gastrointestinal Events Revisited Based on Documents From Recent Litigation"],"prefix":"10.1016","volume":"342","author":[{"given":"David Y.","family":"Graham","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas P.","family":"Jewell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis K.L.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2004","series-title":"The truth about the drug companies. How they deceive us and what to do about it","author":"Angell","key":"10.1097\/MAJ.0b013e3182113658_bb0010"},{"year":"2005","series-title":"Selling sickness. How the world\u2019s biggest pharmaceutical companies are turning us all into patients","author":"Moynihan","key":"10.1097\/MAJ.0b013e3182113658_bb0015"},{"year":"2008","series-title":"Our daily med. How the pharmaceutical companies transformed themselves into slick marketing machines and hooked the nation on prescription drugs","author":"Petersen","key":"10.1097\/MAJ.0b013e3182113658_bb0020"},{"key":"10.1097\/MAJ.0b013e3182113658_bb0025","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1001\/jama.299.15.1800","article-title":"Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation","volume":"299","author":"Ross","year":"2008","journal-title":"JAMA"},{"key":"10.1097\/MAJ.0b013e3182113658_bb0030","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.cgh.2007.03.011","article-title":"Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review","volume":"5","author":"Rostom","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1097\/MAJ.0b013e3182113658_bb0035","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1111\/j.1365-2036.2004.01935.x","article-title":"Review article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications\u2014review and recommendations based on risk assessment","volume":"19","author":"Chan","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1097\/MAJ.0b013e3182113658_bb0040","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1053\/j.gastro.2008.02.007","article-title":"NSAIDs, risks, and gastroprotective strategies: current status and future","volume":"134","author":"Graham","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1097\/MAJ.0b013e3182113658_bb0045","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1001\/jama.282.20.1929","article-title":"Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs","volume":"282","author":"Langman","year":"1999","journal-title":"JAMA"},{"key":"10.1097\/MAJ.0b013e3182113658_bb0050","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1185\/030079904X3078","article-title":"The upper gastrointestinal safety of rofecoxib vs. NSAIDs: an updated combined analysis","volume":"20","author":"Watson","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"10.1097\/MAJ.0b013e3182113658_bb0055","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","article-title":"Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group","volume":"343","author":"Bombardier","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1097\/MAJ.0b013e3182113658_bb0060","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1053\/gast.2002.36013","article-title":"Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis","volume":"123","author":"Laine","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1097\/MAJ.0b013e3182113658_bb0065","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1053\/gast.2003.50054","article-title":"Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use","volume":"124","author":"Laine","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1097\/MAJ.0b013e3182113658_bb0070","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1053\/gast.2001.21907","article-title":"Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient","volume":"120","author":"Laine","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1097\/MAJ.0b013e3182113658_bb0075","doi-asserted-by":"crossref","first-page":"23S","DOI":"10.1016\/S0002-9343(97)00207-6","article-title":"Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury","volume":"104","author":"Griffin","year":"1998","journal-title":"Am J Med"},{"issue":"suppl 2","key":"10.1097\/MAJ.0b013e3182113658_bb0080","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/rheumatology\/39.suppl_2.13","article-title":"Epidemiology and pharmacoeconomic implications of non-steroidal anti-inflammatory drug-associated gastrointestinal toxicity","volume":"39","author":"MacDonald","year":"2000","journal-title":"Rheumatology (Oxford)"},{"key":"10.1097\/MAJ.0b013e3182113658_bb0085","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2165\/11534590-000000000-00000","article-title":"Identification of NSAID users at risk for gastrointestinal complications: a systematic review of current guidelines and consensus agreements","volume":"33","author":"Tielemans","year":"2010","journal-title":"Drug Saf"},{"key":"10.1097\/MAJ.0b013e3182113658_bb0090","doi-asserted-by":"crossref","first-page":"257","DOI":"10.7326\/0003-4819-114-4-257","article-title":"Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons","volume":"114","author":"Griffin","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1097\/MAJ.0b013e3182113658_bb0095","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0140-6736(94)91843-0","article-title":"Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs","volume":"343","author":"Garcia Rodriguez","year":"1994","journal-title":"Lancet"},{"key":"10.1097\/MAJ.0b013e3182113658_bb0100","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1053\/j.gastro.2006.12.007","article-title":"Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population","volume":"132","author":"Garcia Rodriguez","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1097\/MAJ.0b013e3182113658_bb0105","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1136\/bmj.312.7046.1563","article-title":"Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis","volume":"312","author":"Henry","year":"1996","journal-title":"BMJ"},{"key":"10.1097\/MAJ.0b013e3182113658_bb0110","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/1529-0131(200002)43:2<370::AID-ANR17>3.0.CO;2-D","volume":"43","author":"Hawkey","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1097\/MAJ.0b013e3182113658_bb0115","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S0016-5085(99)70334-3","article-title":"A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group","volume":"117","author":"Laine","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1097\/MAJ.0b013e3182113658_bb0120","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.cgh.2009.06.006","article-title":"Endoscopic ulcers are neither meaningful nor validated as a surrogate for clinically significant upper gastrointestinal harm","volume":"7","author":"Graham","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1097\/MAJ.0b013e3182113658_bb0125","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0016-5085(99)70358-6","article-title":"Cyclooxygenase 2 selective inhibitors: panacea or flash in the pan?","volume":"117","author":"Beejay","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1097\/MAJ.0b013e3182113658_bb0130","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1053\/j.gastro.2006.11.012","article-title":"Peptic ulcer and bleeding events associated with rofecoxib in a 3-year colorectal adenoma chemoprevention trial","volume":"132","author":"Lanas","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1097\/MAJ.0b013e3182113658_bb0135","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1136\/bmj.325.7365.624","article-title":"Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs","volume":"325","author":"Mamdani","year":"2002","journal-title":"BMJ"},{"key":"10.1097\/MAJ.0b013e3182113658_bb0140","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1136\/bmj.331.7528.1310","article-title":"Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis","volume":"331","author":"Hippisley-Cox","year":"2005","journal-title":"BMJ"},{"key":"10.1097\/MAJ.0b013e3182113658_bb0145","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1136\/gut.2005.080754","article-title":"Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations","volume":"55","author":"Lanas","year":"2006","journal-title":"Gut"},{"key":"10.1097\/MAJ.0b013e3182113658_bb0150","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1592\/phco.29.12.1397","article-title":"Risk of upper gastrointestinal complications associated with cyclooxygenase-2 selective and nonselective nonsteroidal antiinflammatory drugs","volume":"29","author":"Castellsague","year":"2009","journal-title":"Pharmacotherapy"},{"key":"10.1097\/MAJ.0b013e3182113658_bb0155","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2165\/00002018-200427060-00005","article-title":"Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents","volume":"27","author":"Laporte","year":"2004","journal-title":"Drug Saf"},{"key":"10.1097\/MAJ.0b013e3182113658_bb0160","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1001\/archinte.160.14.2093","article-title":"Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding\/perforation: an overview of epidemiologic studies published in the 1990s","volume":"160","author":"Hernandez-Diaz","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1097\/MAJ.0b013e3182113658_bb0165","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1093\/aje\/153.11.1089","article-title":"Steroids and risk of upper gastrointestinal complications","volume":"153","author":"Hernandez-Diaz","year":"2001","journal-title":"Am J Epidemiol"},{"year":"2009","series-title":"STATA Statistical software","key":"10.1097\/MAJ.0b013e3182113658_bb0170"},{"key":"10.1097\/MAJ.0b013e3182113658_bb0175","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables (with discussion)","volume":"34","author":"Cox","year":"1972","journal-title":"J Royal Stat Soc B"},{"key":"10.1097\/MAJ.0b013e3182113658_bb0180","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1053\/j.gastro.2007.01.017","article-title":"Selective COX-2 inhibitors: a promise unfulfilled?","volume":"132","author":"Henry","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1097\/MAJ.0b013e3182113658_bb0185","first-page":"2080","article-title":"Nonsteroidal anti-inflammatory drugs, Helicobacter pylori, and ulcers: where we stand","volume":"91","author":"Graham","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"10.1097\/MAJ.0b013e3182113658_bb0190","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/clpt.1985.136","article-title":"Nonsteroidal anti-inflammatory effect of sulindac sulfoxide and sulfide on gastric mucosa","volume":"38","author":"Graham","year":"1985","journal-title":"Clin Pharmacol Ther"},{"key":"10.1097\/MAJ.0b013e3182113658_bb0195","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1001\/archfami.9.10.1124","article-title":"Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs: a 6-week and a 1-year trial in patients with osteoarthritis. Osteoarthritis Studies Group","volume":"9","author":"Saag","year":"2000","journal-title":"Arch Fam Med"},{"key":"10.1097\/MAJ.0b013e3182113658_bb0200","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1002\/art.27412","article-title":"Variability of risk of upper gastrointestinal bleeding among nonsteroidal anti-inflammatory drugs","volume":"62","author":"Gonzalez","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1097\/MAJ.0b013e3182113658_bb0205","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.cgh.2008.06.021","article-title":"Small bowel injury by low-dose enteric-coated aspirin and treatment with misoprostol: a pilot study","volume":"6","author":"Watanabe","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1097\/MAJ.0b013e3182113658_bb0210","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.cgh.2008.12.019","article-title":"Low-dose aspirin affects the small bowel mucosa: results of a pilot study with a multidimensional assessment","volume":"7","author":"Smecuol","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1097\/MAJ.0b013e3182113658_bb0215","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3109\/00365520903453182","article-title":"Randomized, double-blind, pilot study of geranylgeranylacetone versus placebo in patients taking low-dose enteric-coated aspirin. Low-dose aspirin-induced small bowel damage","volume":"45","author":"Shiotani","year":"2010","journal-title":"Scand J Gastroenterol"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962915311307?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962915311307?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T16:51:02Z","timestamp":1741798262000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962915311307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S0002962915311307"],"URL":"https:\/\/doi.org\/10.1097\/maj.0b013e3182113658","relation":{},"ISSN":["0002-9629"],"issn-type":[{"type":"print","value":"0002-9629"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}